These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 32686970)
1. Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere? Imbimbo BP; Ippati S; Watling M Expert Opin Drug Discov; 2020 Nov; 15(11):1241-1251. PubMed ID: 32686970 [TBL] [Abstract][Full Text] [Related]
2. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. Imbimbo BP; Lozupone M; Watling M; Panza F Expert Opin Investig Drugs; 2020 Sep; 29(9):919-933. PubMed ID: 32657175 [TBL] [Abstract][Full Text] [Related]
4. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738 [TBL] [Abstract][Full Text] [Related]
5. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. Kalra J; Khan A Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363 [TBL] [Abstract][Full Text] [Related]
6. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis. Lee M; McGeer E; McGeer PL Neurobiol Aging; 2015 Jan; 36(1):42-52. PubMed ID: 25169677 [TBL] [Abstract][Full Text] [Related]
7. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein. Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210 [TBL] [Abstract][Full Text] [Related]
8. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234 [TBL] [Abstract][Full Text] [Related]
9. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease? Doig AJ; Del Castillo-Frias MP; Berthoumieu O; Tarus B; Nasica-Labouze J; Sterpone F; Nguyen PH; Hooper NM; Faller P; Derreumaux P ACS Chem Neurosci; 2017 Jul; 8(7):1435-1437. PubMed ID: 28586203 [TBL] [Abstract][Full Text] [Related]
10. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives. Suzuki N; Hatta T; Ito M; Kusakabe KI Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936 [TBL] [Abstract][Full Text] [Related]
11. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease. Shin J Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001 [No Abstract] [Full Text] [Related]
12. [Pathological changes induced by amyloid-β in Alzheimer's disease]. Takata K; Kitamura Y; Taniguchi T Yakugaku Zasshi; 2011 Jan; 131(1):3-11. PubMed ID: 21212607 [TBL] [Abstract][Full Text] [Related]
13. Status and future directions of clinical trials in Alzheimer's disease. Plascencia-Villa G; Perry G Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008 [TBL] [Abstract][Full Text] [Related]
14. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. Koychev I; Hofer M; Friedman N J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121 [TBL] [Abstract][Full Text] [Related]
15. Progress in the development of new drugs in Alzheimer's disease. Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520 [TBL] [Abstract][Full Text] [Related]
16. Role of tau protein in Alzheimer's disease: The prime pathological player. Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025 [TBL] [Abstract][Full Text] [Related]
17. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. Bloom GS JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463 [TBL] [Abstract][Full Text] [Related]
18. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"]. Tamaoka A Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113 [TBL] [Abstract][Full Text] [Related]
19. APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics. Hussain I CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):395-402. PubMed ID: 20522015 [TBL] [Abstract][Full Text] [Related]
20. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps]. Kuzuhara S Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]